Business

Cypress Bioscience of San Diego, California has aquired worldwide licensing rights for Alexza Pharmaceutical’s Staccato Nicotine inhaler for smoking cessation. Alexza will receive $5 million up front, with another $1 million due upon meeting preclinical… Read more . . .

Skye Pharma says that it understands why Abbot has decided to return US marketing rights for the Flutiform formoterol fluticasate MDI given the issues raised by the US FDA concerning approval of the drug. According… Read more . . .

Archimedes Pharma, which has submitted an NDA for its lead product, PecFent fentanyl nasal spray, announced that it anticipates creating as many as 75 new jobs at its new US headquarters in Bedminster, NJ. The… Read more . . .

MannKind Corporation, which is waiting for FDA approval of its Afrezza inhaled insulin, announced that it hopes to raise up to $110 million by lending 9 million shares of its stock to Bank of America.… Read more . . .

Cannabis Science and Smokefree Innotec will co-develop pharmaceutical cannabis products for inhalation. Smokefree Innotec, which manufactures electronic cigarettes, will develop the devices, with Cannabis Science developing the formulations. Read the company’s press release Read more . . .

RTS Life Sciences has formed RTL Life Science LLC, based near Boston, MA.  RTS manufactures automated inhaler testing systems. Read the company’s press release. Read more . . .

Vectura will license dry powder formulation technology to GlaxoSmithKline for use in respiratory products for up to £20 million. The deal is for worldwide rights and is non-exclusive. Read the company’s press release. Read more . . .